An acidosis-sparing ketogenic (ASK) diet to improve efficacy and reduce adverse effects in the treatment of refractory epilepsy

Epilepsy and Behavior

Volumn 74, Issue , 2017, Pages 15-21

  Yuen, Alan W C ^a,b   Walcutt, Isabel A ^c   Sander, Josemir W ^a,b,d  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b Chalfont Centre for Epilepsy   (United Kingdom)

^c Stichting Epilepsie Instellingen Nederland ^*  (United States)

^d STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

Author keywords

ASIC; Inflammation; Ketones; Low grade chronic metabolic acidosis; Mitochondria

Indexed keywords

ACIDOSIS; ACIDOSIS SPARING KETOGENIC DIET; CARBOHYDRATE INTAKE; CLINICAL EFFECTIVENESS; DIET RESTRICTION; DRUG RESISTANT EPILEPSY; HUMAN; HYDRATION; INTRACTABLE EPILEPSY; KETOACIDOSIS; KETOGENIC DIET; METABOLIC ACIDOSIS; MINERAL INTAKE; MORTALITY RISK; POPULATION RESEARCH; PROTEIN INTAKE; REVIEW; RISK REDUCTION; VEGETABLE; ADMINISTRATION AND DOSAGE; DIET THERAPY; FAT INTAKE; METABOLISM; PROCEDURES; TREATMENT OUTCOME;

KETONE BODY;

ACIDOSIS; DIET, KETOGENIC; DIETARY FATS; DRUG RESISTANT EPILEPSY; HUMANS; KETONE BODIES; KETOSIS; TREATMENT OUTCOME;

EID: 85021328889     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2017.05.032     Document Type: Review

References (88)

1. Kelly, M.T., Hays, T.L., Implementing the ketogenic diet. Top Clin Nutr 13 (1997), 53–61.
2. Wheless, J.W., History of the ketogenic diet. Epilepsia 49:Suppl. 8 (2008), 3–5.
3. Brodie, M.J., Road to refractory epilepsy: the Glasgow story. Epilepsia 54:Suppl. 2 (2013), 5–8.
4. Pizzorno, J., Frassetto, L.A., Katzinger, J., Diet-induced acidosis: is it real and clinically relevant?. Br J Nutr 103 (2010), 1185–1194.
5. Milllichap, J.G., Jones, J.D., Acid–base, electrolyte, and amino-acid metabolism in children with petit mal. Etiologic significance and modification by anticonvulsant drugs and the ketogenic diet. Epilepsia 5 (1964), 239–255.
6. Takeoka, M., Riviello, J.J. Jr., Pfeifer, H., Thiele, E.A., Concomitant treatment with topiramate and ketogenic diet in pediatric epilepsy. Epilepsia 43 (2002), 1072–1075.
7. Yancy, W.S. Jr., Olsen, M.K., Dudley, T., Westman, E.C., Acid–base analysis of individuals following two weight loss diets. Eur J Clin Nutr 61 (2007), 1416–1422.
8. Kang, H.C., Chung, D.E., Kim, D.W., Kim, H.D., Early- and late-onset complications of the ketogenic diet for intractable epilepsy. Epilepsia 45 (2004), 1116–1123.
9. Melamed, P., Melamed, F., Chronic metabolic acidosis destroys pancreas. JOP 15 (2014), 552–560.
10. McNally, M.A., Pyzik, P.L., Rubenstein, J.E., Hamdy, R.F., Kossoff, E.H., Empiric use of potassium citrate reduces kidney-stone incidence with the ketogenic diet. Pediatrics 124 (2009), e300–e304.
11. Hahn, T.J., Halstead, L.R., DeVivo, D.C., Disordered mineral metabolism produced by ketogenic diet therapy. Calcif Tissue Int 28 (1979), 17–22.
12. Bergqvist, A.G., Schall, J.I., Stallings, V.A., Zemel, B.S., Progressive bone mineral content loss in children with intractable epilepsy treated with the ketogenic diet. Am J Clin Nutr 88 (2008), 1678–1684.
13. Arnett, T.R., Extracellular pH regulates bone cell function. J Nutr 138 (2008), 415S–418S.
14. Adeva, M.M., Souto, G., Diet-induced metabolic acidosis. Clin Nutr 30 (2011), 416–421.
15. Chen, W., Melamed, M.L., Abramowitz, M.K., Serum bicarbonate and bone mineral density in US adults. Am J Kidney Dis 65 (2015), 240–248.
16. Groesbeck, D.K., Bluml, R.M., Kossoff, E.H., Long-term use of the ketogenic diet in the treatment of epilepsy. Dev Med Child Neurol 48 (2006), 978–981.
17. Vining, E.P., Pyzik, P., McGrogan, J., Hladky, H., Anand, A., Kriegler, S., et al. Growth of children on the ketogenic diet. Dev Med Child Neurol 44 (2002), 796–802.
18. Williams, S., Basualdo-Hammond, C., Curtis, R., Schuller, R., Growth retardation in children with epilepsy on the ketogenic diet: a retrospective chart review. J Am Diet Assoc 102 (2002), 405–407.
19. Hsu, S.Y., Tsai, I.J., Tsau, Y.K., Comparison of growth in primary Fanconi syndrome and proximal renal tubular acidosis. Pediatr Nephrol 20 (2005), 460–464.
20. de- Brito Ashurst, I., O'Lone, E., Kaushik, T., McCafferty, K., Yaqoob, M.M., Acidosis: progression of chronic kidney disease and quality of life. Pediatr Nephrol 30 (2015), 873–879.
21. Best, T.H., Franz, D.N., Gilbert, D.L., Nelson, D.P., Epstein, M.R., Cardiac complications in pediatric patients on the ketogenic diet. Neurology 54 (2000), 2328–2330.
22. Krishtal, O.A., Pidoplichko, V.I., Receptor for protons in the membrane of sensory neurons. Brain Res 214 (1981), 150–154.
23. Waldmann, R., Champigny, G., Bassilana, F., Heurteaux, C., Lazdunski, M., A proton-gated cation channel involved in acid-sensing. Nature 386 (1997), 173–177.
24. Magnotta, V.A., Heo, H.Y., Dlouhy, B.J., Dahdaleh, N.S., Follmer, R.L., Thedens, D.R., et al. Detecting activity-evoked pH changes in human brain. Proc Natl Acad Sci U S A 109 (2012), 8270–8273.
25. Somjen, G.G., Acidification of interstitial fluid in hippocampal formation caused by seizures and by spreading depression. Brain Res 311 (1984), 186–188.
26. Ziemann, A.E., Schnizler, M.K., Albert, G.W., Severson, M.A., Howard, M.A. III, Welsh, M.J., et al. Seizure termination by acidosis depends on ASIC1a. Nat Neurosci 11 (2008), 816–822.
27. Cao, Q., Wang, W., Gu, J., Jiang, G., Wang, K., Xu, Z., et al. Elevated expression of acid-sensing ion channel 3 inhibits epilepsy via activation of interneurons. Mol Neurobiol 53:1 (2014), 485–498.
28. Yuen, A.W., Low-grade chronic metabolic acidosis is a contributory mechanism in the development of chronic epilepsy. Epilepsy Behav 8 (2006), 347–349.
29. Tsuda, M., Shimizu, N., Yajima, Y., Suzuki, T., Misawa, M., Hypersusceptibility to DMCM-induced seizures during diazepam withdrawal in mice: evidence for upregulation of NMDA receptors. Naunyn Schmiedebergs Arch Pharmacol 357 (1998), 309–315.
30. Tsai, G., Coyle, J.T., The role of glutamatergic neurotransmission in the pathophysiology of alcoholism. Annu Rev Med 49 (1998), 173–184.
31. Miller, J.W., Stopping seizures with carbon dioxide. Epilepsy Curr 11 (2011), 114–115.
32. Li, F., Liu, X., Su, Z., Sun, R., Acidosis leads to brain dysfunctions through impairing cortical GABAergic neurons. Biochem Biophys Res Commun 410 (2011), 775–779.
33. Vezzani, A., Epilepsy and inflammation in the brain: overview and pathophysiology. Epilepsy Curr 14 (2014), 3–7.
34. Dupuis, N., Auvin, S., Inflammation and epilepsy in the developing brain: clinical and experimental evidence. CNS Neurosci Ther 21 (2015), 141–151.
35. Shimada, T., Takemiya, T., Sugiura, H., Yamagata, K., Role of inflammatory mediators in the pathogenesis of epilepsy. Mediators Inflamm, 2014, 2014, 901902.
36. Kellum, J.A., Song, M., Li, J., Science review: extracellular acidosis and the immune response: clinical and physiologic implications. Crit Care 8 (2004), 331–336.
37. Liamis, G., Milionis, H.J., Elisaf, M., Pharmacologically-induced metabolic acidosis: a review. Drug Saf 33 (2010), 371–391.
38. Ridker, P.M., Cushman, M., Stampfer, M.J., Tracy, R.P., Hennekens, C.H., Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336 (1997), 973–979.
39. Erlinger, T.P., Muntner, P., Helzlsouer, K.J., WBC count and the risk of cancer mortality in a national sample of U.S. adults: results from the second National Health and Nutrition Examination Survey mortality study. Cancer Epidemiol Biomarkers Prev 13 (2004), 1052–1056.
40. Ruggiero, C., Metter, E.J., Cherubini, A., Maggio, M., Sen, R., Najjar, S.S., et al. White blood cell count and mortality in the Baltimore Longitudinal Study of Aging. J Am Coll Cardiol 49 (2007), 1841–1850.
41. Farwell, W.R., Taylor, E.N., Serum anion gap, bicarbonate and biomarkers of inflammation in healthy individuals in a national survey. CMAJ 182 (2010), 137–141.
42. Raphael, K.L., Zhang, Y., Wei, G., Greene, T., Cheung, A.K., Beddhu, S., Serum bicarbonate and mortality in adults in NHANES III. Nephrol Dial Transplant 28 (2013), 1207–1213.
43. Park, M., Jung, S.J., Yoon, S., Yun, J.M., Yoon, H.J., Association between the markers of metabolic acid load and higher all-cause and cardiovascular mortality in a general population with preserved renal function. Hypertens Res 38 (2015), 433–438.
44. Murakami, K., Sasaki, S., Takahashi, Y., Uenishi, K., Association between dietary acid–base load and cardiometabolic risk factors in young Japanese women. Br J Nutr 100 (2008), 642–651.
45. Souto, G., Donapetry, C., Calvino, J., Adeva, M.M., Metabolic acidosis-induced insulin resistance and cardiovascular risk. Metab Syndr Relat Disord 9 (2011), 247–253.
46. DeFronzo, R.A., Beckles, A.D., Glucose intolerance following chronic metabolic acidosis in man. Am J Physiol 236 (1979), E328–E334.
47. Reaich, D., Graham, K.A., Channon, S.M., Hetherington, C., Scrimgeour, C.M., Wilkinson, R., et al. Insulin-mediated changes in PD and glucose uptake after correction of acidosis in humans with CRF. Am J Physiol 268 (1995), E121–E126.
48. Fagherazzi, G., Vilier, A., Bonnet, F., Lajous, M., Balkau, B., Boutron-Rualt, M.C., et al. Dietary acid load and risk of type 2 diabetes: the E3N-EPIC cohort study. Diabetologia 57 (2014), 313–320.
49. Driver, T.H., Shlipak, M.G., Katz, R., Goldenstein, L., Sarnak, M.J., Hoofnagle, A.N., et al. Low serum bicarbonate and kidney function decline: the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis 64 (2014), 534–541.
50. Vollmer, L.L., Strawn, J.R., Sah, R., Acid–base dysregulation and chemosensory mechanisms in panic disorder: a translational update. Transl Psychiatry, 5, 2015, e572.
51. Brungger, M., Hulter, H.N., Krapf, R., Effect of chronic metabolic acidosis on thyroid hormone homeostasis in humans. Am J Physiol 272 (1997), F648–F653.
52. Weitzel, J.M., Iwen, K.A., Coordination of mitochondrial biogenesis by thyroid hormone. Mol Cell Endocrinol 342 (2011), 1–7.
53. Boland, M.L., Chourasia, A.H., Macleod, K.F., Mitochondrial dysfunction in cancer. Front Oncol, 3, 2013, 292.
54. Lane, R.K., Hilsabeck, T., Rea, S.L., The role of mitochondrial dysfunction in age-related diseases. Biochim Biophys Acta 2015 (1847), 1387–1400.
55. Montgomery, M.K., Turner, N., Mitochondrial dysfunction and insulin resistance: an update. Endocr Connect 4 (2015), R1–R15.
56. Pieczenik, S.R., Neustadt, J., Mitochondrial dysfunction and molecular pathways of disease. Exp Mol Pathol 83 (2007), 84–92.
57. Yuen, A.W., Sander, J.W., Impaired mitochondrial energy production: the basis of pharmacoresistance in epilepsy. Med Hypotheses 77 (2011), 536–540.
58. Schoeler, N.E., Cross, J.H., Sander, J.W., Sisodiya, S.M., Can we predict a favourable response to Ketogenic Diet Therapies for drug-resistant epilepsy?. Epilepsy Res 106 (2013), 1–16.
59. Likhodii, S.S., Musa, K., Mendonca, A., Dell, C., Burnham, W.M., Cunnane, S.C., Dietary fat, ketosis, and seizure resistance in rats on the ketogenic diet. Epilepsia 41 (2000), 1400–1410.
60. Cunnane, S.C., Metabolism of polyunsaturated fatty acids and ketogenesis: an emerging connection. Prostaglandins Leukot Essent Fatty Acids 70 (2004), 237–241.
61. Eagles, D.A., Boyd, S.J., Kotak, A., Allan, F., Calorie restriction of a high-carbohydrate diet elevates the threshold of PTZ-induced seizures to values equal to those seen with a ketogenic diet. Epilepsy Res 54 (2003), 41–52.
62. Frassetto, L.A., Todd, K.M., Morris, R.C. Jr., Sebastian, A., Estimation of net endogenous noncarbonic acid production in humans from diet potassium and protein contents. Am J Clin Nutr 68 (1998), 576–583.
63. Evangeliou, A., Spilioti, M., Doulioglou, V., Kalaidopoulou, P., Ilias, A., Skarpalezou, A., et al. Branched chain amino acids as adjunctive therapy to ketogenic diet in epilepsy: pilot study and hypothesis. J Child Neurol 24 (2009), 1268–1272.
64. Layman, D.K., Anthony, T.G., Rasmussen, B.B., Adams, S.H., Lynch, C.J., Brinkworth, G.D., et al. Defining meal requirements for protein to optimize metabolic roles of amino acids. Am J Clin Nutr 101:6 (2015), 1330S–1338S.
65. Yuen, A.W., Sander, J.W., Can magnesium supplementation reduce seizures in people with epilepsy? A hypothesis. Epilepsy Res 100 (2012), 152–156.
66. Osborn, K.E., Shytle, R.D., Frontera, A.T., Soble, J.R., Schoenberg, M.R., Addressing potential role of magnesium dyshomeostasis to improve treatment efficacy for epilepsy: a reexamination of the literature. J Clin Pharmacol 56:3 (2015), 260–265.
67. Abdelmalik, P.A., Politzer, N., Carlen, P.L., Magnesium as an effective adjunct therapy for drug resistant seizures. Can J Neurol Sci 39 (2012), 323–327.
68. Zou, L.P., Wang, X., Dong, C.H., Chen, C.H., Zhao, W., Zhao, R.Y., Three-week combination treatment with ACTH + magnesium sulfate versus ACTH monotherapy for infantile spasms: a 24-week, randomized, open-label, follow-up study in China. Clin Ther 32 (2010), 692–700.
69. Kitterer, D., Schwab, M., Alscher, M.D., Braun, N., Latus, J., Drug-induced acid–base disorders. Pediatr Nephrol 30 (2015), 1407–1423.
70. Sheth, R.D., Metabolic concerns associated with antiepileptic medications. Neurology 63 (2004), S24–S29.
71. German, J.B., Dillard, C.J., Saturated fats: a perspective from lactation and milk composition. Lipids 45 (2010), 915–923.
72. Sun, Y., Vestergaard, M., Christensen, J., Olsen, J., Breastfeeding and risk of epilepsy in childhood: a birth cohort study. J Pediatr 158 (2011), 924–929.
73. Pekala, J., Patkowska-Sokola, B., Bodkowski, R., Jamroz, D., Nowakowski, P., Lochynski, S., et al. L-carnitine—metabolic functions and meaning in humans life. Curr Drug Metab 12 (2011), 667–678.
74. Purchas, R.W., Rutherfurd, S.M., Pearce, P.D., Vather, R., Wilkinson, B.H., Concentrations in beef and lamb of taurine, carnosine, coenzyme Q(10), and creatine. Meat Sci 66 (2004), 629–637.
75. Keyser, A., De Bruijn, S.F., Epileptic manifestations and vitamin B1 deficiency. Eur Neurol 31 (1991), 121–125.
76. Yuen, A.W., Sander, J.W., Can natural ways to stimulate the vagus nerve improve seizure control?. Epilepsy Behav 67 (2017), 105–110.
77. Karami-Mohajeri, S., Abdollahi, M., Toxic influence of organophosphate, carbamate, and organochlorine pesticides on cellular metabolism of lipids, proteins, and carbohydrates: a systematic review. Hum Exp Toxicol 30 (2011), 1119–1140.
78. Masino, S.A., Kawamura, M., Wasser, C.D., Pomeroy, L.T., Ruskin, D.N., Adenosine, ketogenic diet and epilepsy: the emerging therapeutic relationship between metabolism and brain activity. Curr Neuropharmacol 7 (2009), 257–268.
79. Wurtman, R.J., Synapse formation and cognitive brain development: effect of docosahexaenoic acid and other dietary constituents. Metabolism 57:Suppl. 2 (2008), S6–10.
80. Meyer, J.N., Leung, M.C., Rooney, J.P., Sendoel, A., Hengartner, M.O., Kisby, G.E., et al. Mitochondria as a target of environmental toxicants. Toxicol Sci 134 (2013), 1–17.
81. Finsterer, J., Segall, L., Drugs interfering with mitochondrial disorders. Drug Chem Toxicol 33 (2010), 138–151.
82. Finsterer, J., Zarrouk, M.S., Mitochondrial toxicity of antiepileptic drugs and their tolerability in mitochondrial disorders. Expert Opin Drug Metab Toxicol 8 (2012), 71–79.
83. Neal, E.G., Chaffe, H., Schwartz, R.H., Lawson, M.S., Edwards, N., Fitzsimmons, G., et al. The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. Lancet Neurol 7 (2008), 500–506.
84. Lambrechts, D.A., de Kinderen, R.J., Vles, J.S., de Louw, A.J., Aldenkamp, A.P., Majoie, H.J., A randomized controlled trial of the ketogenic diet in refractory childhood epilepsy. Acta Neurol Scand 135:2 (2016), 231–239.
85. Winesett, S.P., Bessone, S.K., Kossoff, E.H., The ketogenic diet in pharmacoresistant childhood epilepsy. Expert Rev Neurother 15 (2015), 621–628.
86. Auvin, S., Non-pharmacological medical treatment in pediatric epilepsies. Rev Neurol (Paris) 172 (2016), 182–185.
87. Ye, F., Li, X.J., Jiang, W.L., Sun, H.B., Liu, J., Efficacy of and patient compliance with a ketogenic diet in adults with intractable epilepsy: a meta-analysis. J Clin Neurol 11 (2015), 26–31.
88. Cervenka, M.C., Henry, B.J., Felton, E.A., Patton, K., Kossoff, E.H., Establishing an adult epilepsy diet center: experience, efficacy and challenges. Epilepsy Behav 58 (2016), 61–68.